We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Test Detects Bacterial Infection in Autoimmune Diseases

By LabMedica International staff writers
Posted on 19 Jun 2012
The serum procalcitonin test (PCT) has been used to detect bacterial infection in patients with autoimmune diseases.

The clinical manifestations of disease flare and infection overlap and are identified by similar laboratory markers so there is an urgent need for a reliable biomarker that discriminates early infection from disease flare in febrile patients with autoimmune disease (AD). More...


Scientists from Chang Gung University (Tao Yuan, Taiwan) have reviewed studies carried out between January 1966 and October 2011 that had evaluated PCT as a diagnostic marker for bacterial infection in patients with AD, which included nine studies for PCT and five studies for C-reactive protein (CRP).

In healthy individuals, serum PCT is normally undetectable below 0.05 ng/mL, but the level increases rapidly after bacterial infection. In contrast to CRP, PCT does not rise with noninfectious inflammation or nonbacterial infections, making it a potentially useful marker to distinguish bacterial infection from disease flare in the setting of autoimmune disease.

The positive likelihood ratio for PCT was sufficiently high to be qualified as a rule-in diagnostic tool, while the negative likelihood ratio was not sufficiently low to be qualified as a reliable rule-out diagnostic tool. The area under the receiver-operating curve was higher for PCT than for CRP. Both markers had suboptimal negative likelihood ratios and so are not suitable tests for excluding bacterial infection in febrile patients with autoimmune diseases.

The authors conclude that different cut off levels are needed to optimize the discriminative capability of PCT for different autoimmune diseases. However, this requires a large study or studies of patients with the same autoimmune disease.

Until the results of such studies are available, they recommend using a standard PCT cut off value of 0.5 ng/mL, which has reasonable sensitivity of 76% and specificity of 88%.

Shy-Shin Chang, MD, lead author of the study said, "Analysis of the pooled data suggests that PCT is a more specific indicator of bacterial infection than CRP, but that CRP is a more sensitive indicator of bacterial infection than PCT." The study was published online on May 17, 2012, in the journal Arthritis and Rheumatism.

Related Links:
Chang Gung University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.